Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 5
2011 3
2013 2
2014 2
2015 2
2016 2
2017 1
2018 3
2019 5
2020 4
2021 4
2022 9
2023 9
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Bylicki O, et al. Among authors: decroisette c. Eur J Cancer. 2023 Apr;183:38-48. doi: 10.1016/j.ejca.2023.01.014. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801605 Free article. Clinical Trial.
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Among authors: decroisette c. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.
Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, Duruisseaux M. Chour A, et al. Among authors: decroisette c. J Thorac Oncol. 2023 Oct;18(10):1408-1415. doi: 10.1016/j.jtho.2023.05.013. Epub 2023 May 20. J Thorac Oncol. 2023. PMID: 37217096 Free article.
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, Arpin D, Morel H, Veillon R, Justeau G, Huchot E, Fournel P, Vergnenegre A, Bizeux A, Subtil F, Clarisse B, Decroisette C, Chouaid C, Greillier L, Bylicki O. Amari L, et al. Among authors: decroisette c. Lung Cancer. 2024 Jul;193:107843. doi: 10.1016/j.lungcan.2024.107843. Epub 2024 May 31. Lung Cancer. 2024. PMID: 38830303 Free article. Clinical Trial.
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.
Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradère P, Zaidan M, Decroisette C, Fallah F, Matergia G, Lavaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM. Velev M, et al. Among authors: decroisette c. Eur J Cancer. 2023 Jan;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Epub 2022 Nov 12. Eur J Cancer. 2023. PMID: 36473326
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaïd C, Guisier F. Dhamelincourt E, et al. Among authors: decroisette c. Target Oncol. 2023 Nov;18(6):905-914. doi: 10.1007/s11523-023-01014-z. Epub 2023 Nov 15. Target Oncol. 2023. PMID: 37966566
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Decroisette C, Greillier L, Curcio H, Pérol M, Ricordel C, Auliac JB, Falchero L, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Game L, Bernardi M, Doubre H, Pinsolle J, Amrane K, Chouaïd C, Descourt R. Decroisette C, et al. J Immunother. 2023 Oct 9. doi: 10.1097/CJI.0000000000000490. Online ahead of print. J Immunother. 2023. PMID: 37807621
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Descourt R, Greillier L, Perol M, Ricordel C, Auliac JB, Falchero L, Gervais R, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Game L, Bernardi M, Fournel P, Doubre H, Pinsolle J, Amrane K, Chouaïd C, Decroisette C. Descourt R, et al. Among authors: decroisette c. Cancer Immunol Immunother. 2023 Jan;72(1):91-99. doi: 10.1007/s00262-022-03232-2. Epub 2022 Jun 21. Cancer Immunol Immunother. 2023. PMID: 35729418 Free PMC article.
44 results